User login
Key clinical point: Lactobacillus rhamnosus, with or without other probiotics, reduced the incidence risk for atopic dermatitis (AD) in children when administered to mothers and infants in the perinatal period.
Major finding: The risk of developing AD was significantly reduced at 2 years (risk ratio [RR] 0.60; P < .00001) and 6-7 years (RR 0.62; P < .00001) with L. rhamnosus or L. rhamnosus + other probiotic strains.
Study details: Findings are from a meta-analysis of 11 randomized controlled trials that reported the incidence of AD after oral administration of L. rhamnosus or L. rhamnasos + other probiotics during pregnancy and post-pregnancy in mothers and infants.
Disclosures: J Voigt received partial funding. The authors declared serving as an evidence assessment expert or an executive for Lil Mixins, a manufacturer of probiotic supplements.
Source: Voigt J and Lele M. Lactobacillus rhamnosus used in the perinatal period for the prevention of atopic dermatitis in infants: A systematic review and meta-analysis of randomized trials. Am J Clin Dermatol. 2022;23:801–811 (Sep 26). Doi: 10.1007/s40257-022-00723-x
Key clinical point: Lactobacillus rhamnosus, with or without other probiotics, reduced the incidence risk for atopic dermatitis (AD) in children when administered to mothers and infants in the perinatal period.
Major finding: The risk of developing AD was significantly reduced at 2 years (risk ratio [RR] 0.60; P < .00001) and 6-7 years (RR 0.62; P < .00001) with L. rhamnosus or L. rhamnosus + other probiotic strains.
Study details: Findings are from a meta-analysis of 11 randomized controlled trials that reported the incidence of AD after oral administration of L. rhamnosus or L. rhamnasos + other probiotics during pregnancy and post-pregnancy in mothers and infants.
Disclosures: J Voigt received partial funding. The authors declared serving as an evidence assessment expert or an executive for Lil Mixins, a manufacturer of probiotic supplements.
Source: Voigt J and Lele M. Lactobacillus rhamnosus used in the perinatal period for the prevention of atopic dermatitis in infants: A systematic review and meta-analysis of randomized trials. Am J Clin Dermatol. 2022;23:801–811 (Sep 26). Doi: 10.1007/s40257-022-00723-x
Key clinical point: Lactobacillus rhamnosus, with or without other probiotics, reduced the incidence risk for atopic dermatitis (AD) in children when administered to mothers and infants in the perinatal period.
Major finding: The risk of developing AD was significantly reduced at 2 years (risk ratio [RR] 0.60; P < .00001) and 6-7 years (RR 0.62; P < .00001) with L. rhamnosus or L. rhamnosus + other probiotic strains.
Study details: Findings are from a meta-analysis of 11 randomized controlled trials that reported the incidence of AD after oral administration of L. rhamnosus or L. rhamnasos + other probiotics during pregnancy and post-pregnancy in mothers and infants.
Disclosures: J Voigt received partial funding. The authors declared serving as an evidence assessment expert or an executive for Lil Mixins, a manufacturer of probiotic supplements.
Source: Voigt J and Lele M. Lactobacillus rhamnosus used in the perinatal period for the prevention of atopic dermatitis in infants: A systematic review and meta-analysis of randomized trials. Am J Clin Dermatol. 2022;23:801–811 (Sep 26). Doi: 10.1007/s40257-022-00723-x